Akademik Veri Yönetim Sistemi
Updates in Autoimmune Diseases , Luis Rodrigo, Editör, IntechOpen, London, ss.1-24, 2025
Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) has emerged as a distinct clinical entity within the spectrum of central nervous system inflammatory demyelinating disorders. Recent advances have refined its nosological classification, distinguishing it from both multiple sclerosis and aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder. The identification of myelin oligodendrocyte glycoprotein-immunoglobulin G through highly specific cell-based assays has been pivotal in recognizing a broader clinical phenotype, including recurrent optic neuritis, longitudinally extensive transverse myelitis, and cerebral cortical encephalitis. Ongoing research highlights differences in immunopathogenesis, relapse risk, and long-term outcomes compared to other demyelinating conditions. Moreover, recent studies support the efficacy of early and sustained immunotherapy, with corticosteroids, intravenous immunoglobulin, and rituximab showing benefits in relapse prevention. Emerging biomarkers and novel therapeutic targets are currently under investigation, offering promising directions for personalized management. This section provides an overview of the current diagnosis and clinical approaches to treating MOGAD.